Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036933 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00036933: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00036933 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036933, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with QS21 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with QS21 in treating patients who have prostate cancer.
Interventions
- BIOLOGICAL QS21
- BIOLOGICAL MUC-2-Globo H-KLH conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2002-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036933
The ClinicalTrials.gov registry entry for NCT00036933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QS21 is the first listed.
NCT00036933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036933 about?
NCT00036933 is a clinical study titled "Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with QS21 may kill more tumor cells. PURPOSE: Phase II trial to study...
What is the current status of trial NCT00036933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2002-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00036933?
The interventions under investigation include: QS21 (BIOLOGICAL), MUC-2-Globo H-KLH conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00036933?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.